Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...
Judd Klingerman's selected project will take him to Madrid, Spain, for six weeks this summer.
Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.
Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...